Compare AES Corp (AES) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AES Corp vs Amylx Pharmaceuticals Inc — how do they compare? AES Corp trades at $14.72 (market cap $10.51B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B). The key difference: AES Corp is far larger — about 4.2× Amylx Pharmaceuticals Inc's market cap, and AES Corp pays a 4.78% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AES | AMLX | |
|---|---|---|
Market Cap | $10.51B | $2.53B |
Sector | Utilities | Health |
52-Week High | $17.28 | $24.19 |
52-Week Low | $12.51 | $7.82 |
Enterprise Value | $40.77B | $2.28B |
Dividend Yield | 4.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
